TransMedics Group (TMDX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$12.89 (-15.14%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of TransMedics Group (TMDX)
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Key Insights

Critical company metrics and information
  • Share Price

    $71.72
  • Market Cap

    $2.41 Billion
  • Total Outstanding Shares

    33.56 Million Shares
  • Total Employees

    584
  • Dividend

    No dividend
  • IPO Date

    May 2, 2019
  • SIC Description

    Electromedical & Electrotherapeutic Apparatus
  • Homepage

    https://www.transmedics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$6.86 Million
Net Cash Flow From Investing Activities$-47.76 Million
Net Cash Flow From Financing Activities$7.86 Million
Net Cash Flow, Continuing$-33.04 Million
Exchange Gains/Losses$386000.00
Net Cash Flow$-32.66 Million
Net Cash Flow From Financing Activities, Continuing$7.86 Million
Net Cash Flow From Investing Activities, Continuing$-47.76 Million
Net Cash Flow From Operating Activities, Continuing$6.86 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Revenues$108.76 Million
Nonoperating Income/Loss$322000.00
Cost Of Revenue$47.92 Million
Research and Development$14.27 Million
Net Income/Loss Attributable To Parent$4.22 Million
Costs And Expenses$104.52 Million
Net Income/Loss Available To Common Stockholders, Basic$4.22 Million
Basic Earnings Per Share$0.13
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations After Tax$4.22 Million
Income Tax Expense/Benefit, Current$29000.00
Operating Income/Loss$3.92 Million
Benefits Costs and Expenses$104.52 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations Before Tax$4.25 Million
Operating Expenses$56.92 Million
Income Tax Expense/Benefit$29000.00
Selling, General, and Administrative Expenses$42.66 Million
Diluted Average Shares$35.68 Million
Net Income/Loss$4.22 Million
Diluted Earnings Per Share$0.12
Gross Profit$60.84 Million
Basic Average Shares$33.44 Million
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Liabilities$575.65 Million
Noncurrent Assets$293.10 Million
Noncurrent Liabilities$515.60 Million
Accounts Payable$13.13 Million
Equity$209.92 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Assets$440.32 Million
Current Assets$492.48 Million
Fixed Assets$271.74 Million
Current Liabilities$60.05 Million
Other Non-current Assets$19.16 Million
Other Current Liabilities$26.15 Million
Intangible Assets$2.20 Million
Equity Attributable To Parent$209.92 Million
Wages$20.77 Million
Liabilities And Equity$785.57 Million
Assets$785.57 Million
Inventory$52.15 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.